The -938A/A genotype of BCL2 gene is associated with esophageal cancer

Medical Oncology

Volumn 29, Issue 4, 2012, Pages 2677-2683

  Liu, Zhigang ^a,b   Sun, Ruifang ^c   Lü, Weidong ^a   Dang, Chengxue ^b   Song, Yangrong ^a   Wang, Cheng ^a   Zhang, Xi ^a   Han, Le ^a   Cheng, Hao ^a   Gao, Wei ^a   Liu, Jia ^a   Lei, Guangyan ^a  

^a Tumor Hospital of Shannxi Province   (China)

^b THE FIRST AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

^c XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

Apoptosis; BAX; BCL2; Demographic characteristics; Esophageal cancer; Polymorphism

Indexed keywords

PROTEIN BAX; PROTEIN BCL 2;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER RISK; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CASE CONTROL STUDY; CONTROLLED STUDY; ESOPHAGUS CANCER; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; ONCOGENE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; TUMOR DIFFERENTIATION;

ADULT; AGED; BCL-2-ASSOCIATED X PROTEIN; ESOPHAGEAL NEOPLASMS; FEMALE; GENES, BCL-2; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC;

EID: 84867994775     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-011-0135-2     Document Type: Article

References (34)

1. He J, Gu D, Wu X, Reynolds K, Duan X, Yao C, Wang J, Chen CS, Chen J, Wildman RP, et al. Major causes of death among men and women in China. N Engl J Med. 2005;353(11):1124-34.
2. Holmes RS, Vaughan TL. Epidemiology and pathogenesis of esophageal cancer. Semin Radiat Oncol. 2007;17(1):2-9.
3. Hao B, Wang H, Zhou K, Li Y, Chen X, Zhou G, Zhu Y, Miao X, Tan W, Wei Q. Identification of genetic variants in base excision repair pathway and their associations with risk of esophageal squamous cell carcinoma. Cancer Res. 2004;64(12):4378-84.
4. Tang DG, Porter AT. Target to apoptosis: a hopeful weapon for prostate cancer. Prostate. 1997;32(4):284-93.
5. Faderl S, Keating MJ, Do KA, Liang SY, Kantarjian HM, O'Brien S, Garcia-Manero G, Manshouri T, Albitar M. Expression profile of 11 proteins and their prognostic significance in patients with chronic lymphocytic leukemia (CLL). Leukemia. 2002;16(6):1045-52.
6. Keshgegian AA, Johnston E, Cnaan A. Bcl-2 oncoprotein positivity and high MIB-1 (Ki-67) proliferative rate are independent predictive markers for recurrence in prostate carcinoma. Am J Clin Pathol. 1998;110(4):443-9.
7. Ofner D, Riehemann K, Maier H, Riedmann B, Nehoda H, Totsch M, Bocker W, Jasani B, Schmid KW. Immunohistochemically detectable bcl-2 expression in colorectal carcinoma: correlation with tumour stage and patient survival. Br J Cancer. 1995;72(4):981-5.
8. Zhang GJ, Kimijima I, Tsuchiya A, Abe R. The role of bcl-2 expression in breast carcinomas (Review). Oncol Rep. 1998;5(5):1211-6.
9. Fontanini G, Vignati S, Bigini D, Mussi A, Lucchi M, Angeletti CA, Basolo F, Bevilacqua G. Bcl-2 protein: a prognostic factor inversely correlated to p53 in non-small-cell lung cancer. Br J Cancer. 1995;71(5):1003-7.
10. Hirata H, Hinoda Y, Nakajima K, Kikuno N, Suehiro Y, Tabatabai ZL, Ishii N, Dahiya R. The bcl2-938CC genotype has poor prognosis and lower survival in renal cancer. J Urol. 2009;182(2):721-7.
11. Lehnerdt GF, Franz P, Bankfalvi A, Grehl S, Kelava A, Nuckel H, Lang S, Schmid KW, Siffert W, Bachmann HS. The regulatory BCL2 promoter polymorphism (-938C>A) is associated with relapse and survival of patients with oropharyngeal squamous cell carcinoma. Ann Oncol. 2009;20(6):1094-9.
12. Aguilar-Santelises M, Rottenberg ME, Lewin N, Mellstedt H, Jondal M. Bcl-2, Bax and p53 expression in B-CLL in relation to in vitro survival and clinical progression. Int J Cancer. 1996;69(2):114-9.
13. Pepper C, Hoy T, Bentley DP. Bcl-2/Bax ratios in chronic lymphocytic leukaemia and their correlation with in vitro apoptosis and clinical resistance. Br J Cancer. 1997;76(7):935-8.
14. Kidd LR, Coulibaly A, Templeton TM, Chen W, Long LO, Mason T, Bonilla C, Akereyeni F, Freeman V, Isaacs W, et al. Germline BCL-2 sequence variants and inherited predisposition to prostate cancer. Prostate Cancer Prostatic Dis. 2006;9(3):284-92.
15. Chen K, Hu Z, Wang LE, Sturgis EM, El-Naggar AK, Zhang W, Wei Q. Single-nucleotide polymorphisms at the TP53-binding or responsive promoter regions of BAX and BCL2 genes and risk of squamous cell carcinoma of the head and neck. Carcinogenesis. 2007;28(9):2008-12.
16. Komaki S, Kohno M, Matsuura N, Shimadzu M, Adachi N, Hoshide R, Nishiyama S, Matsuda I. The polymorphic 43Thr bcl-2 protein confers relative resistance to autoimmunity: an analytical evaluation. Hum Genet. 1998;103(4):435-40.
17. Jain M, Kumar S, Lal P, Tiwari A, Ghoshal UC, Mittal B. Role of BCL2 (ala43thr), CCND1 (G870A) and FAS (A-670G) polymorphisms in modulating the risk of developing esophageal cancer. Cancer Detect Prev. 2007;31(3):225-32.
18. Fegan C, Starczynski J, Pratt G, Pepper C. The role of the bax gene polymorphism G(-248)A in chronic lymphocytic leukemia. Leukemia. 2006;20(8):1460-1.
19. Nuckel H, Frey UH, Sellmann L, Bau M, Durig J, Duhrsen U, Siffert W. Bax gene G(-248)A promoter polymorphism and chronic lymphocytic leukemia: lack of association with incidence, disease stage and progression-free survival. Leukemia. 2006;20(4):724.
20. Skogsberg S, Tobin G, Krober A, Kienle D, Thunberg U, Aleskog A, Karlsson K, Laurell A, Merup M, Vilpo J, et al. The G(-248)A polymorphism in the promoter region of the Bax gene does not correlate with prognostic markers or overall survival in chronic lymphocytic leukemia. Leukemia. 2006;20(1):77-81.
21. Watanabe H, Jass JR, Sobin LH, Ota K. International histological classification of tumors. 2nd ed. Berlin, New York: Springer-Verlag; 1990.
22. Zhang N, Li XY, Tao K, Jiang LY, Ma TT, Yan S, Yuan CZ, Moran MS, Liang FM, Haffty BG, et al. BCL-2 (-938C > A) polymorphism is associated with breast cancer susceptibility. BMC Med Genet. 2011. doi: 10.1186/1471-2350-12-48.
23. Ocana MG, Valle-Garay E, Montes AH, Meana A, Carton JA, Fierer J, Celada A, Asensi V. Bax gene G(-248)A promoter polymorphism is associated with increased lifespan of the neutrophils of patients with osteomyelitis. Genet Med. 2007;9(4):249-55.
24. Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature. 1990;348(6299):334-6.
25. Metzger R, Schneider PM, Warnecke-Eberz U, Brabender J, Holscher AH. Molecular biology of esophageal cancer. Onkologie. 2004;27(2):200-6.
26. Ohbu M, Saegusa M, Kobayashi N, Tsukamoto H, Mieno H, Kakita A, Okayasu I. Expression of bcl-2 protein in esophageal squamous cell carcinomas and its association with lymph node metastasis. Cancer. 1997;79(7):1287-93.
27. Park BL, Kim LH, Cheong HS, Cho HY, Kim EM, Shin HD, Kim YS, Lee C. Identification of variants in cyclin D1 (CCND1) and B-Cell CLL/lymphoma 2 (BCL2). J Hum Genet. 2004;49(8):449-54.
28. Bachmann HS, Otterbach F, Callies R, Nuckel H, Bau M, Schmid KW, Siffert W, Kimmig R. The AA genotype of the regulatory BCL2 promoter polymorphism (938C>A) is associated with a favorable outcome in lymph node negative invasive breast cancer patients. Clin Cancer Res. 2007;13(19):5790-7.
29. Heubner M, Wimberger P, Otterbach F, Kasimir-Bauer S, Siffert W, Kimmig R, Nuckel H. Association of the AA genotype of the BCL2 (-938C > A) promoter polymorphism with better survival in ovarian cancer. Int J Biol Markers. 2009;24(4):223-9.
30. Hirata H, Hinoda Y, Kikuno N, Suehiro Y, Shahryari V, Ahmad AE, Tabatabai ZL, Igawa M, Dahiya R. Bcl2-938C/A polymorphism carries increased risk of biochemical recurrence after radical prostatectomy. J Urol. 2009;181(4):1907-12.
31. Young RL, Korsmeyer SJ. A negative regulatory element in the bcl-2 5′-untranslated region inhibits expression from an upstream promoter. Mol Cell Biol. 1993;13(6):3686-97.
32. Nuckel H, Frey UH, Bau M, Sellmann L, Stanelle J, Durig J, Jockel KH, Duhrsen U, Siffert W. Association of a novel regulatory polymorphism (-938C>A) in the BCL2 gene promoter with disease progression and survival in chronic lymphocytic leukemia. Blood. 2007;109(1):290-7.
33. Bachmann HS, Heukamp LC, Schmitz KJ, Hilburn CF, Kahl P, Buettner R, Nuckel H, Eisenhardt A, Rubben H, Schmid KW, et al. Regulatory BCL2 promoter polymorphism (-938C>A) is associated with adverse outcome in patients with prostate carcinoma. Int J Cancer. 2011;129(10):2390-9.
34. Stewart WB, Kleihues P. World cancer report. Lyon: IARC Press; 2003, ISBN 92-832-0411-5.